Newsletter summary
Text of news flash
[understandable] April 12thLightnitecryptoIn a research paper published in the journal Cell, Xu Jie's team of Shanghai Medical College of Fudan University discovered the first ligand CD3L1 (or ITPRIPL1) of CD3.LightnitecryptoThis finding reveals the key role of CD3L1 in tumor immune escape and testicular immune immunity, and provides a new target for tumor immunotherapy. The first report of CD3L1 antibody indicates a new breakthrough in the field of tumor immunotherapy. In this study, scientists revealed the relationship between CD3L1 and CD3 for the first time, which is of great significance for understanding the mechanism of tumor immunotherapy. The research and application of CD3L1 antibody is expected to bring more effective treatment for patients. This discovery not only provides a new research direction for researchers, but also brings new market opportunities for related enterprises and investors. With the continuous development of tumor immunotherapy, this breakthrough will provide more possibilities for the treatment of cancer and other diseases in the future. Hexun self-selected Stock Writer risk Tip: the above content is only the views of the author or guest, does not represent any position of Hexun, and does not constitute any investment advice related to Hexun. Before making any investment decision, investors should consider the risk factors related to investment products according to their own circumstances and consult professional investment advisers if necessary. Hexun tries its best but cannot confirm the authenticity, accuracy and originality of the above content, and Hexun does not make any guarantee or commitment.
